Development of a Real-Time PCR Assay for Detection of
 Plasmodium falciparum
 ,
 Plasmodium vivax
 , and
 Plasmodium ovale
 for Routine Clinical Diagnosis

Perandin, Francesca; Manca, N.; Calderaro, Adriana; Piccolo, Giovanna; Galati, L.; Ricci, Lucila Costallat; Medici, Maria Cristina; Arcangeletti, Maria Cristina; Snounou, Georges; Dettori, G.; Chezzi, Carlo

doi:10.1128/jcm.42.3.1214-1219.2004

Cited by 298 publications

(327 citation statements)

References 23 publications

Supporting

Mentioning

295

Contrasting

Unclassified

Order By: Relevance

“…These assays enable detection of the four Plasmodium parasite species that infect humans at densities ~100 times lower than the limit of LM detection [47] and have evolved from simple species-specific amplification strategies to multiplex approaches that incorporate semiquantitative assessments [31,[49][50][51][52][53][54][55][56]. We have greatly extended the potential use of PCR diagnosis for a wide range of epidemiological studies through our recent efforts to develop a ligase detection reaction fluorescent microsphere assay (LDR-FMA) [52,57] to evaluate all four malaria parasites of humans in a single-well multiplex format.…”

Section: Improved Diagnosis Of P Malariae and P Ovale Infections Bymentioning

confidence: 99%

Plasmodium malariae and Plasmodium ovale – the ‘bashful’ malaria parasites

Müeller

Zimmerman

Reeder

2007

Trends in Parasitology

270

245

View full text Add to dashboard Cite

Although Plasmodium malariae was first described as an infectious disease of humans by Golgi in 1886 and Plasmodium ovale identified by Stevens in 1922, there are still large gaps in our knowledge of the importance of these infections as causes of malaria in different parts of the world. They have traditionally been thought of as mild illnesses that are caused by rare and, in case of P. ovale, short-lived parasites. However, recent advances in sensitive PCR diagnosis are causing a re-evaluation of this assumption. Low-level infection seems to be common across malaria-endemic areas, often as complex mixed infections. The potential interactions of P. malariae and P. ovale with Plasmodium falciparum and Plasmodium vivax might explain some basic questions of malaria epidemiology, and understanding these interactions could have an important influence on the deployment of interventions such as malaria vaccines. Geographical distributionAlthough distribution of Plasmodium malariae infection is reported as being patchy, it has been observed in all major malaria-endemic regions of the world [1]. P. malariae infections are most common in sub-Saharan Africa and the southwest Pacific, where age-specific prevalence in mass blood surveys have exceeded 15-30% [2][3][4][5][6][7][8]. By contrast, when P. malariae has been detected in malaria-endemic regions of Asia [9][10][11][12], the Middle East [13], South America [14] and Central America [15], it is observed as an infrequent infection, with blood-smear light microscopy (LM) prevalence rarely exceeding 1-2%. Much higher levels of infection were, however, found in montagnard refugees from the Cambodian-Vietnamese border [16]. In South America, P. malariae is thought to be a zoonotic infection because the genetically identical Plasmodium brasilianum infects new-world monkeys [17] and both monkeys and humans in endemic areas show high levels of seropositivity to P. malariae and P. brasilianum antigens [18].Plasmodium ovale was thought to have a much more limited distribution, with endemic transmission traditionally described as being limited to areas of tropical Africa, New Guinea, the eastern parts of Indonesia and the Philippines [19,20]. Infections with P. ovale, however, have also been reported in the Middle East [13], the Indian subcontinent [21] and different parts of Southeast Asia [11,22,23]. In West Africa (and to a lesser extent Central Africa), age specific LM prevalence of >10% have been observed [3,6] places where P. ovale is observed, it is relatively uncommon and its prevalence (as detected by LM) rarely exceeds 3-5% [22,[24][25][26].Indepth descriptions of the epidemiology of both infections based upon LM data are, thus, restricted almost exclusively to highly endemic areas in Africa and the Southwest Pacific. Detailed epidemiological studies from South America and Asia are lacking. Variation in parasite prevalenceIn West Africa, P. malariae prevalence has been reported to peak at ages similar to those of P. falciparum (i.e. in children under ten years of...

show abstract

Section: Improved Diagnosis Of P Malariae and P Ovale Infections Bymentioning

confidence: 99%

Plasmodium malariae and Plasmodium ovale – the ‘bashful’ malaria parasites

Müeller

Zimmerman

Reeder

2007

Trends in Parasitology

270

245

View full text Add to dashboard Cite

show abstract

“…This method has been used for genome numbers estimation and diagnostic detection of parasites, such as Plasmodium spp. (Perandin et al 2004) and T. gondii (Buchbinder et al 2003).…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and prognostic value of cell free circulating Schistosoma mansoni DNA: an experimental study

Eraky

Aly

2014

J Parasit Dis

View full text Add to dashboard Cite

Searching for a more sensitive and accurate marker for schistosomiasis diagnosis and treatment follow up is a potential necessity. Hereby, we evaluated usefulness of circulating free DNA as a marker for schistosomiasis diagnosis, assessing drug efficacy and monitoring the control interventions impact using SYBR green real-time PCR. A batch of mice were infected by 90 ± 10 Schistosoma mansoni cercariae. Starting from the 2nd day post infection (p.i.), groups of 2 or 3 mice were sacrificed every 3 days until 30 days p.i. The remaining animals were treated by a single dose of 400 mg/kg mefloquine and sacrificed in group at 5, 10, 21 days post treatment (35, 40, 51 days p.i.). Using SYBR green real time qPCR, pooled sera DNA were extracted and amplified. The results showed that, circulating free S. mansoni DNA was detected from the 2nd day post infection (p.i.) onwards with gradual decrease in the cycle threshold value C t which indicates the gradual elevation of the DNA level (Log quantity was 2.6-3.1 IU/ml), As the infection progressed, DNA quantity was increased(Log quantity was 6.29 IU/ml). Initial increase of circulating free DNA was observed 10 days post treatment (40 days p.i.) (Log quantity was 7.38 IU/ ml). That was followed by a progressive decrease in DNA level by the end of 21st day, post treatment (51 p.i.) (Log quantity 4.35 IU/ml). In conclusion, circulating free S. mansoni DNA is a reliable marker in the diagnosis of schistosomiasis and for assessing drug efficacy and monitoring the impact of control interventions.

show abstract

“…The parasite density of P. vivax was determined by real-time quantitative PCR (14,21), and P. vivax-positive samples were genotyped for the highly polymorphic PvDBPII alleles (22).…”

mentioning

confidence: 99%

Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection

King

Michon

Shakri

et al. 2008

Proc. Natl. Acad. Sci. U.S.A.

158

209

View full text Add to dashboard Cite

Individuals residing in malaria-endemic regions acquire protective immunity after repeated infection with malaria parasites; however, mechanisms of protective immunity and their immune correlates are poorly understood. Blood-stage infection with Plasmodium vivax depends completely on interaction of P. vivax Duffy-binding protein (PvDBP) with the Duffy antigen on host erythrocytes. Here, we performed a prospective cohort treatment/reinfection study of children (5-14 years) residing in a P. vivax-endemic region of Papua New Guinea (PNG) in which children were cleared of blood-stage infection and then examined biweekly for reinfection for 25 weeks. To test the hypothesis that naturally acquired binding inhibitory antibodies (BIAbs) targeting PvDBP region II (PvDBPII) provide protection against P. vivax infection, we used a quantitative receptor-binding assay to distinguish between antibodies that merely recognize PvDBP and those that inhibit binding to Duffy. The presence of high-level BIAbs (>90% inhibition of PvDBPII-Duffy binding, n ‫؍‬ 18) before treatment was associated with delayed time to P. vivax reinfection diagnosed by light microscopy (P ‫؍‬ 0.02), 55% reduced risk of P. vivax reinfection (Hazard's ratio ‫؍‬ 0.45, P ‫؍‬ 0.04), and 48% reduction in geometric mean P. vivax parasitemia (P < 0.001) when compared with children with low-level BIAbs (n ‫؍‬ 148). Further, we found that stable, high-level BIAbs displayed strain-transcending inhibition by reducing reinfection with similar efficiency of PNG P. vivax strains characterized by six diverse PvDBPII haplotypes. These observations demonstrate a functional correlate of protective immunity in vivo and provide support for developing a vaccine against P. vivax malaria based on PvDBPII.Duffy antigen ͉ immunity ͉ protective antibodies P rotective immunity against malaria is acquired by residents of endemic regions over a period of years after repeated exposure to malaria parasites (1). Naturally acquired immunity to Plasmodium falciparum and Plasmodium vivax malaria does not prevent infection by these parasites completely, but limits parasite densities, reduces the frequency of clinical malaria episodes, and prevents severe disease (2). Humoral immune responses against blood-stage antigens are an important component of naturally acquired immunity to malaria (2, 3). Therefore, parasite proteins engaged in erythrocyte invasion are potential targets of protective antibody responses.Interaction between P. vivax Duffy-binding protein (PvDBP) and the Duffy antigen receptor (DA) on host erythrocytes is central to blood-stage infection by P. vivax (4, 5). Adhesion to DA is mediated by the 140-kDa PvDBP (6-8). The receptor-binding domain of PvDBP maps to the conserved, N-terminal cysteine-rich region II (PvDBPII) (9, 10). Given the complete dependence of P. vivax on the PvDBPII-Duffy interaction for blood-stage infection and recent observations that PvDBPII-specific antibodies inhibit P. vivax invasion of human erythrocytes in vitro (11), we examined the hypothesis that...

show abstract

Development of a Real-Time PCR Assay for Detection of Plasmodium falciparum , Plasmodium vivax , and Plasmodium ovale for Routine Clinical Diagnosis

Cited by 298 publications

References 23 publications

Plasmodium malariae and Plasmodium ovale – the ‘bashful’ malaria parasites

Plasmodium malariae and Plasmodium ovale – the ‘bashful’ malaria parasites

Diagnostic and prognostic value of cell free circulating Schistosoma mansoni DNA: an experimental study

Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection

Contact Info

Product

Resources

About